Advertisement
Screener

KALA BIO, INC. (KALA) Number of Reportable Segments

2.8 / 5 stars · 68/120 Roast Me

KALA BIO, INC. Number of Reportable Segments

KALA BIO, INC. (KALA) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.

Financial Statements › Notes › Segment Reporting

us-gaap:NumberOfReportableSegments · last filed 2026-08-19

  • KALA BIO, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
  • KALA BIO, INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment.
  • KALA BIO, INC. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
  • KALA BIO, INC. number of reportable segments for fiscal 2024 was 1.00 segment.
Period endNumber of Reportable Segments 3 monthNumber of Reportable Segments 6 monthNumber of Reportable Segments 9 monthNumber of Reportable Segments 12 month
2026-06-301.00 segment
10-Q · filed 2026-08-19
2026-03-311.00 segment
10-Q · filed 2026-05-15
2025-12-311.00 segment
10-K · filed 2026-04-15
2025-09-301.00 segment
10-Q · filed 2025-11-19
2025-06-301.00 segment
10-Q · filed 2025-08-08
2025-03-311.00 segment
10-Q · filed 2025-05-14
2024-12-311.00 segment
10-K · filed 2025-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
MetaVia Inc. (MTVA)United States$0.011B-0.65
Moleculin Biotech, Inc. (MBRX)United States$0.011B
Theriva Biologics, Inc. (TOVX)United States$0.011B
Azitra, Inc. (AZTR)United States$0.010B-0.81
Dare Bioscience, Inc. (DARE)United States$0.011B
Medicus Pharma Ltd. (MDCX)$0.010B
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92